The DOI matches its Crossref record; 197 of the 197 references it cites were found in a registry or an index.
Opioid antagonists for alcohol dependence
Abstract
BACKGROUND: Alcohol dependence belongs to the globally leading health risk factors. Therapeutic success of psychosocial programs for relapse prevention is moderate and could be increased by an adjuvant treatment with the opioid antagonists naltrexone and nalmefene. OBJECTIVES: To determine the effectiveness and tolerability of opioid antagonists in the treatment of alcohol dependence. SEARCH STRATEGY: We searched the Cochrane Drugs and Alcohol Group (CDAG) Specialized Register, PubMed, EMBASE and CINAHL in January 2010 and inquired manufacturers and researchers for unpublished trials. SELECTION CRITERIA: All double-blind randomised controlled trials (RCTs) which compare the effects of naltrexone or nalmefene with placebo or active control on drinking-related outcomes. DATA COLLECTION AND ANALYSIS: Two authors independently extracted outcome data. Trial quality was assessed by one author and cross-checked by a second author. MAIN RESULTS: Based on a total of 50 RCTs with 7793 patients, naltrexone reduced the risk of heavy drinking to 83% of the risk in the placebo group RR 0.83 (95% CI 0.76 to 0.90) and decreased drinking days by about 4%, MD -3.89 (95% CI -5.75 to -2.04). Significant effects were also demonstrated for the secondary outcomes of the review including heavy drinking days, MD - 3.25 (95% CI -5.51 to -0.99), consumed amount of alcohol, MD - 10.83 (95% CI -19.69 to -1.97) and gamma-glutamyltransferase, MD - 10.37 (95% CI -18.99 to -1.75), while effects on return to any drinking, RR 0.96 (95 CI 0.92 to 1.00) missed statistical significance. Side effects of naltrexone were mainly gastrointestinal problems (e.g. nausea: RD 0.10; 95% CI 0.07 to 0.13) and sedative effects (e.g. daytime sleepiness: RD 0.09; 95% CI 0.05 to 0.14). Based on a limited study sample, effects of injectable naltrexone and nalmefene missed statistical significance. Effects of industry-sponsored studies, RR 0.90 (95% CI 0.78 to 1.05) did not significantly differ from those of non-profit funded trials, RR 0.84 (95% CI 0.77 to 0.91) and the linear regression test did not indicate publication bias (P = 0.765). AUTHORS' CONCLUSIONS: Naltrexone appears to be an effective and safe strategy in alcoholism treatment. Even though the sizes of treatment effects might appear moderate in their magnitudes, these should be valued against the background of the relapsing nature of alcoholism and the limited therapeutic options currently available for its treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Kessler, R. C. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950010008002 · Cited by 12,370
Cohen, J. (1992) · Psychological Bulletin · doi:10.1037//0033-2909.112.1.155 · Cited by 8,771
Confirmation Bias: A Ubiquitous Phenomenon in Many Guises
Nickerson, R. S. (1998) · Review of General Psychology · doi:10.1037/1089-2680.2.2.175 · Cited by 7,267
Schulz (1995) · doi:10.1001/jama.1995.03520290060030 · Cited by 5,634
The Hopkins Symptom Checklist (HSCL): A self-report symptom inventory
Derogatis, L. R., Lipman, R. S., Rickels, K., Uhlenhuth, E. H., & Covi, L. (1974) · Behavioral Science · doi:10.1002/bs.3830190102 · Cited by 4,604
Rehm, J., Mathers, C., Popova, S., Thavorncharoensap, M., Teerawattananon, Y., & Patra, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60746-7 · Cited by 3,870
Cited by
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Industry sponsorship and research outcome
Lundh, A., Lexchin, J., Mintzes, B., Schroll, J. B., & Bero, L. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.mr000033.pub3 · Cited by 1,697
Effectiveness and cost-effectiveness of policies and programmes to reduce the harm caused by alcohol
Anderson, P., Chisholm, D., & Fuhr, D. C. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60744-3 · Cited by 1,102
Treatment and prevention of mental disorders in low-income and middle-income countries
Patel, V., Araya, R., Chatterjee, S., Chisholm, D., Cohen, A., De Silva, M., Hosman, C., McGuire, H., Rojas, G., & van Ommeren, M. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61240-9 · Cited by 930
Garbutt, J. C., Kranzler, H. R., O’Malley, S. S., Gastfriend, D. R., Pettinati, H. M., Silverman, B. L., Loewy, J. W., Ehrich, E. W., & Vivitrex Study Group, F. T. (2005) · JAMA · doi:10.1001/jama.293.13.1617 · Cited by 635
Alcoholism: A Systems Approach From Molecular Physiology to Addictive Behavior
Spanagel, R. (2009) · Physiological Reviews · doi:10.1152/physrev.00013.2008 · Cited by 634
Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials
Krebs, T. S., & Johansen, P.-Ø. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112439253 · Cited by 583
Diagnosis and Pharmacotherapy of Alcohol Use Disorder: A Review
Kranzler, H. R., & Soyka, M. (2018) · JAMA · doi:10.1001/jama.2018.11406 · Cited by 580
Koppaka, V., Thompson, D. C., Chen, Y., Ellermann, M., Nicolaou, K. C., Juvonen, R. O., Petersen, D., Deitrich, R. A., Hurley, T. D., & Vasiliou, V. (2012) · Pharmacological Reviews · doi:10.1124/pr.111.005538 · Cited by 557
Altice, F. L., Kamarulzaman, A., Soriano, V. V., Schechter, M., & Friedland, G. H. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60829-x · Cited by 504
Maisel, N. C., Blodgett, J. C., Wilbourne, P. L., Humphreys, K., & Finney, J. W. (2013) · Addiction · doi:10.1111/j.1360-0443.2012.04054.x · Cited by 470
Leeman, R. F., & Potenza, M. N. (2012) · Psychopharmacology · doi:10.1007/s00213-011-2550-7 · Cited by 448
Randomisation to protect against selection bias in healthcare trials
Odgaard-Jensen, J., Vist, G. E., Timmer, A., Kunz, R., Akl, E. A., Schünemann, H., Briel, M., Nordmann, A. J., Pregno, S., & Oxman, A. D. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.mr000012.pub3 · Cited by 439
Acamprosate for alcohol dependence
Rösner, S., Hackl-Herrwerth, A., Leucht, S., Lehert, P., Vecchi, S., & Soyka, M. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004332.pub2 · Cited by 412
Connor, J. P., Haber, P. S., & Hall, W. D. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00122-1 · Cited by 389
Pharmacological treatment of alcohol dependence: Target symptoms and target mechanisms
HEILIG, M., & EGLI, M. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.02.001 · Cited by 377
Huhn, M., Tardy, M., Spineli, L. M., Kissling, W., Förstl, H., Pitschel-Walz, G., Leucht, C., Samara, M., Dold, M., Davis, J. M., et al. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.112 · Cited by 333
Lingford-Hughes, A., Welch, S., Peters, L., Nutt, D., & With expert reviewers (in alphabetical order): Ball D, B. N. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112444324 · Cited by 332
Alcohol use disorders and mortality: a systematic review and meta-analysis
Roerecke, M., & Rehm, J. (2013) · Addiction · doi:10.1111/add.12231 · Cited by 326
Rösner, S., Leucht, S., Lehert, P., & Soyka, M. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107078308 · Cited by 300
FRIEDLANDER, A. H., MARDER, S. R., PISEGNA, J. R., & YAGIELA, J. A. (2003) · The Journal of the American Dental Association · doi:10.14219/jada.archive.2003.0260 · Cited by 269
Probst, C., Manthey, J., Martinez, A., & Rehm, J. (2015) · Substance Abuse Treatment, Prevention, and Policy · doi:10.1186/s13011-015-0028-z · Cited by 264
Update on neuropharmacological treatments for alcoholism: Scientific basis and clinical findings
Johnson, B. A. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.08.005 · Cited by 264
Rehm, J., Shield, K. D., Gmel, G., Rehm, M. X., & Frick, U. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.08.001 · Cited by 257
Mitchell, J. M., O’Neil, J. P., Janabi, M., Marks, S. M., Jagust, W. J., & Fields, H. L. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3002902 · Cited by 237
Classic hallucinogens in the treatment of addictions
Bogenschutz, M. P., & Johnson, M. W. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.03.002 · Cited by 226
Therapeutic Use of LSD in Psychiatry: A Systematic Review of Randomized-Controlled Clinical Trials
Fuentes, J. J., Fonseca, F., Elices, M., Farré, M., & Torrens, M. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00943 · Cited by 177
Don’t stress about CRF: assessing the translational failures of CRF1antagonists
Spierling, S. R., & Zorrilla, E. P. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4556-2 · Cited by 170
Errors in search strategies were identified by type and frequency
Sampson, M., & McGowan, J. (2006) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2006.01.007 · Cited by 142
Reduction in heavy drinking as a treatment outcome in alcohol dependence
Gastfriend, D. R., Garbutt, J. C., Pettinati, H. M., & Forman, R. F. (2007) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2006.09.008 · Cited by 139
Barr, C. S., Schwandt, M., Lindell, S. G., Chen, S. A., Goldman, D., Suomi, S. J., Higley, J. D., & Heilig, M. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.3.369 · Cited by 105
Alcohol use disorders and ADHD.
Luderer, M., Ramos Quiroga, J. A., Faraone, S. V., Zhang-James, Y., & Reif, A. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.07.010 · Cited by 102
Reduced Drinking in Alcohol Dependence Treatment, What Is the Evidence?
Mann, K., Aubin, H.-J., & Witkiewitz, K. (2017) · European Addiction Research · doi:10.1159/000481348 · Cited by 93
Packages of care for alcohol use disorders in low- and middle-income countries
Benegal, V., Chand, P. K., & Obot, I. S. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000170 · Cited by 94
Lukas, S. E., Lowen, S. B., Lindsey, K. P., Conn, N., Tartarini, W., Rodolico, J., Mallya, G., Palmer, C., & Penetar, D. M. (2013) · NeuroImage · doi:10.1016/j.neuroimage.2013.03.055 · Cited by 83
Turner, D., Briken, P., Grubbs, J., Malandain, L., Mestre-Bach, G., Potenza, M. N., & Thibaut, F. (2022) · Dialogues in Clinical Neuroscience · doi:10.1080/19585969.2022.2134739 · Cited by 86
Alcohol Use Disorders in Opioid Maintenance Therapy: Prevalence, Clinical Correlates and Treatment
Soyka, M. (2015) · European Addiction Research · doi:10.1159/000363232 · Cited by 77
Cohen, A. M., Smalheiser, N. R., McDonagh, M. S., Yu, C., Adams, C. E., Davis, J. M., & Yu, P. S. (2015) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocu025 · Cited by 78
Baclofen for alcohol use disorder
Minozzi, S., Saulle, R., & Rösner, S. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012557.pub2 · Cited by 73
Treatment-refractory substance use disorder: focus on alcohol, opioids, and cocaine
Soyka, M., & Mutschler, J. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.11.003 · Cited by 49
Blanco, C., Okuda, M., Wang, S., Liu, S.-M., & Olfson, M. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.1206 · Cited by 49
Naltrexone in compulsive sexual behavior disorder: a feasibility study of twenty men
Savard, J., Öberg, K. G., Chatzittofis, A., Dhejne, C., Arver, S., & Jokinen, J. (2020) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2020.04.318 · Cited by 45
Turncliff, R., DiPetrillo, L., Silverman, B., & Ehrich, E. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.10.001 · Cited by 36
Woods, A. D., Giometti, R., & Weeks, S. M. (2015) · JBI Database of Systematic Reviews and Implementation Reports · doi:10.11124/jbisrir-2015-1602 · Cited by 23
Shield, K. D., Rehm, J., Rehm, M. X., Gmel, G., & Drummond, C. (2014) · BMC Health Services Research · doi:10.1186/1472-6963-14-53 · Cited by 20
Philippine, T., Forsgren, E., DeWitt, C., Carter, I., McCollough, M., & Taira, B. R. (2022) · BMC Health Services Research · doi:10.1186/s12913-022-07862-1 · Cited by 19
Ng, S.-M., Rentala, S., Chan, C. L. W., & Nayak, R. B. (2020) · Journal of Addictions Nursing · doi:10.1097/jan.0000000000000368 · Cited by 12
Greene, M. C., Kane, J., Alto, M., Giusto, A., Lovero, K., Stockton, M., McClendon, J., Nicholson, T., Wainberg, M. L., Johnson, R. M., et al. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013350.pub2 · Cited by 11
Reuter, A., Beko, B., Memani, B., Furin, J., Daniels, J., Rodriguez, E., Reuter, H., Weich, L., Isaakidis, P., von der Heyden, E., et al. (2022) · Tropical Medicine and Infectious Disease · doi:10.3390/tropicalmed7020021 · Cited by 9
Leroy, A., Carton, L., Gomajee, H., Bordet, R., & Cottencin, O. (2017) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2017.1298117 · Cited by 5
(2014) · Työväentutkimus Vuosikirja · Cited by 1
Metadata
- Authors
- Srisurapanont, M., & Jarusuraisin, N.
- Venue
- The Cochrane Database of Systematic Reviews
- Publisher
- John Wiley & Sons, Ltd
- Published
- 2002-04-22
- Issue
- 12
- Pages
- CD001867-CD001867
- OpenAlex
- W1635084872
- Cited by
- 764
- References
- 197
- Type
- reference entry
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.